Advertisement

Topics

Latest "IONTAS Limited" News Stories

21:27 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "IONTAS Limited" found in our extensive news archives from over 250 global news sources.

More Information about IONTAS Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about IONTAS Limited for you to read. Along with our medical data and news we also list IONTAS Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of IONTAS Limited Companies for you to search.

Showing "IONTAS Limited" News Articles 1–25 of 176

Extremely Relevant

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

IONTAS Limited (IONTAS), a leader in the discovery and optimization of fully human antibodies, announced its Founder and Chief Executive Officer, John McCafferty was invited to attend the Nobel Prize Award Ceremony in recognition of his pivotal contribution to the development of antibody phage display technology.


Relevant

IONTAS founder and phage display pioneer attends Nobel Prize Award Ceremony.

Dr John McCafferty celebrates success of phage display technology with Nobel Prize in Chemistry Laureates Cambridge, UK, 11 December 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced its Founder and Chief Executive Officer, John McCafferty was invited to attend the Nobel Prize Award Ceremony in recognition of his pivotal contribut...

Scientists develop recombinant human antibody panel against snake venom.

Paper published in Nature Communications shows the potential of applying modern recombinant antibody technology to the blight of snake envenomation Collaboration between IONTAS, Cambridge, Instituto Clodomiro Picado (Universidad de Costa Rica), and Technical University of Denmark to develop fully human IgG antibodies that neutralise black mamba snake venom in vivo Cambridge, UK, San...


Scientists Develop Recombinant Human Antibody Panel against Snake Venom

Paper published in Nature Communications shows the potential of applying modern recombinant antibody technology to the blight of snake envenomation Collaboration between IONTAS, Cambridge, Instituto Clodomiro Picado (Universidad de Costa Rica), and Technical University of Denmark to develop fully human IgG antibodies that ne...

IONTAS Founder and Phage Display Pioneer Attends Nobel Prize Award Ceremony

Dr John McCafferty celebrates success of phage display technology with Nobel Prize in Chemistry Laureates IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced its Founder and Chief Executive Officer, John McCafferty was invited to attend the Nobel Prize Award Ceremony in recognition of his pivotal con...

Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data

JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation (V&V) concordance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray. Initial SDS Microarray – Assay Performance Results of the V&V head-to-head study for the ...

Genetic Technologies Limited Provides End of Year Update on the Test Development Program

MELBOURNE, Australia, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, provides today an update on its R&D program for the year. Excellent R&D progress in 2018, approaching commercialisation early in 2019 As announced t...

Aleafia Health Completes Strategic Investment in Australia’s CannaPacific Pty Limited

Global Expansion Underway with 10% Equity Investment in Licensed Cannabis Cultivator CannaPacific among Australia’s only Federally Licensed Cultivators with projected 108,000 sq. ft. Greenhouse TORONTO, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF: OTCQX: ALEAF, FRA: ARAH) (“Aleafia Health”) or the (“Company”) is announcing its global expansion with the closing o...

Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 9,230,770 ordinary shares at a price to the public of $6.50 per share. The net proceeds to the Company from this offering are expected to be approximately $56.1 mi...

Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the offering will be offered by the Company. In addition, the Company intends to grant the underwriters a ...

Genetic Technologies Limited Announces New Biomedical Blockchain Joint Venture

MELBOURNE, Australia, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), via its subsidiary Gene Ventures Pty Ltd, is pleased to announce that it has entered into a joint venture with Blockshine Technology Corporation (BTC). The joint venture (JV) company, called Blockshine Health, will pursue and develop blockchain opportunities in the biome...

Quotient Limited to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

JERSEY, Channel Islands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief Executive Officer, Franz Walt, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:00 a.m. EST at the Lotte New York Palace Hotel, in New York, NY. ...

Quotient Limited to Participate in the Jefferies 2018 London Healthcare Conference

JERSEY, Channel Islands, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chief Financial Officer, Chris Lindop, will present at the Jefferies 2018 London Healthcare Conference on Tuesday, November 14th, 2018 at 8:40 a.m. GMT (3:40 a.m. Eastern Time). A webcast of the presentation will be available online ...

Veritas Signs MOU with Israeli Cannabis Industry Leader IsCann Group Limited

VANCOUVER, British Columbia, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with IsCann Group Limited (“IsCann”) located in Be'er Tuvya, Israel with the aim of establishing, maintaining, and expanding business in the Canad...

Quotient Limited to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference

JERSEY, Channel Islands, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Franz Walt, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3rd, 2018 at 4:00 p.m. EDT at The InterContinental New York Barclay Hotel, in New York, NY.  ...

Quotient Limited Announces Receipt of Consents to Modifications to the Company’s Senior Secured Notes

JERSEY, Channel Islands, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the receipt of consents from the holders of its Senior Secured Notes (the Notes) to certain amendments (the Proposed Amendments) to the indenture governing the Notes (the Indenture).    Franz Walt, Quotient’s Chief Executive Offi...

Genetic Technologies Limited Announces Research Collaboration with Two World-Renowned Medical Centres

MELBOURNE, Australia, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company is pleased to announce the execution of a 3-way Research Agreement between its subsidiary Phenogen (100 % owned), Memorial Sloan Kettering Cancer Center (MSK), New York and the University of Cambridge, UK. This collaborative re...

Quotient Limited to Host Investor Day and Ring Closing Bell at the NASDAQ on March 4, 2019

JERSEY, Channel Islands, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company will host an Investor Day on Monday, March 4, 2019 from 1:00pm – 3:00pm ET, in New York, NY. Following the Investor Day, the Company’s Chief Executive Officer, Franz Walt, will ring the Closing Bell of the NASDAQ Stock Exchange....

Quotient Limited to Report Fiscal Third Quarter 2019 Financial Results and Host Conference Call

JERSEY, Channel Islands, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2018, will be released before market open on Thursday, January 31, 2019. Quotient will host a conference call to discuss its third quarter financial results at 8:30 a.m. East...

Quotient Limited to Report Fiscal Second Quarter 2019 Financial Results and Host Conference Call

JERSEY, Channel Islands, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2018, will be released before market open on Monday, November 5, 2018. Quotient will host a conference call to discuss its second quarter financial results at 8:00 a.m. Easte...

Genetic Technologies Announces Proposed Joint Venture with Beijing Zishan Health Consultancy Limited

MELBOURNE, Australia, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has signed a Heads of Agreement (Agreement) with Beijing Zishan Health Consultancy Limited (Zishan). The Agreement pr...

Genetic Technologies Limited Invited by Representatives of the Hainan Government to Discuss Market Entry into China

MELBOURNE, Australia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Representatives of the Hainan Government - Hainan Ecological Smart City Group (“HESCG”), a Chinese industrial park development & operations company have formally invited Genetic Technologies Limited (“GTG”) to visit the Hainan Medical Pilot Zone to conduct a formal review and discuss opportunities for market entry into China vi...

Quotient Limited Announces Receipt of the ISO 13485:2016 Certification of its State of the Art MosaiQ™ Microarray Manufacturing Facility

JERSEY, Channel Islands, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported receipt of the formal ISO 13485:2016 certification for its state of the art MosaiQ™ multiplexing microarray manufacturing facility following the successful conclusion of the related European regulatory audit in September of this year....

Avalon GloboCare Establishes Joint Venture with Arbele Limited to Co-develop Next-Generation Multi-Targeted CAR-T Cellular Immunotherapy

FREEHOLD, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, announced today that the Company and its wholly owned subsidiary, Avactis Biosciences, have entered into a joint venture and exclusive license agreement with Arbele Limited to co-develop next generation, transposon-based Chimeric Antigen Receptor (CAR)-...

Quotient Limited reports the submission of the initial IH CE mark filing and the successful completion of the key regulatory audits of its new BioCampus facility

Initial IH CE mark submission has been completed and filed on scheduleSuccessful facility audits pave the way for an on time BioCampus ramp up JERSEY, Channel Islands, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported: (i) the submission of its completed dossier for the CE mark of its initial MosaiQ IH product as planned; ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks